N
DXCM icon

Natixis’s DexCom DXCM Stock Holding History

Natixis’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.26M Buy
83,706
+5,845
+8% +$407K 0.02% 422
2025
Q4 		$5.17M Sell
77,861
-28,973
-27% -$1.87M 0.02% 455
2025
Q3 		$7.19M Buy
106,834
+44,121
+70% +$3.49M 0.03% 362
2025
Q2 		$5.47M Buy
62,713
+42,962
+218% +$3.37M 0.02% 339
2025
Q1 		$1.34M Sell
19,751
-11,119
-36% -$907K 0.01% 507
2024
Q4 		$2.4M Sell
30,870
-126,994
-80% -$9.4M 0.01% 436
2024
Q3 		$10.6M Buy
157,864
+68,073
+76% +$5.59M 0.06% 215
2024
Q2 		$10.2M Buy
89,791
+81,791
+1,022% +$10.3M 0.06% 204
2024
Q1 		$1.11M Buy
8,000
+1,600
+25% +$201K 0.01% 513
2023
Q4 		$794K Buy
+6,400
New +$654K 0.01% 562
2023
Q1 		– Sell
-59,549
Closed -$6.74M – 1043
2022
Q4 		$6.74M Buy
59,549
+570
+1% +$62.6K 0.04% 329
2022
Q3 		$4.81M Sell
58,979
-21,223
-26% -$1.8M 0.02% 419
2022
Q2 		$5.99M Sell
80,202
-516,838
-87% -$47.2M 0.02% 403
2022
Q1 		$76.4M Sell
597,040
-145,796
-20% -$15.9M 0.27% 78
2021
Q4 		$99.7M Buy
742,836
+209,440
+39% +$30.1M 0.34% 48
2021
Q3 		$72.9M Buy
533,396
+228,208
+75% +$28.8M 0.25% 74
2021
Q2 		$32.6M Buy
305,188
+155,856
+104% +$15M 0.14% 143
2021
Q1 		$13.4M Sell
149,332
-141,764
-49% -$13.3M 0.04% 324
2020
Q4 		$26.9M Buy
+291,096
New +$26M 0.1% 206
2020
Q2 		– Sell
-175,692
Closed -$11.8M – 765
2020
Q1 		$11.8M Buy
175,692
+136,120
+344% +$8.47M 0.09% 182
2019
Q4 		$2.14M Buy
+39,572
New +$1.88M 0.01% 547
2018
Q4 		– Sell
-29,384
Closed -$1.05M – 716
2018
Q3 		$1.05M Buy
+29,384
New +$911K 0.01% 564
2017
Q3 		– Sell
-41,536
Closed -$760K – 1268
2017
Q2 		$760K Buy
+41,536
New +$767K 0.01% 451

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Natixis's DXCM Position: Q1 2026 in Review

Natixis increased its DexCom (DXCM) stake by 7.5% in Q1 2026, buying an estimated $407K and bringing the position to 83,706 shares worth $5.26M. The position accounts for 0.02% of the portfolio, ranked #422.

Natixis first reported a position in DXCM in Q2 2017 and has held it in 23 quarters since. The position peaked at $99.7M in Q4 2021. 960 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • Natixis held 83,706 shares of DexCom worth $5.26M as of Q1 2026.
  • Natixis bought 5,845 DexCom shares in Q1 2026, an estimated $407K.
  • DexCom made up 0.02% of Natixis's portfolio in Q1 2026, its #422 holding.
  • Natixis first reported a position in DexCom in Q2 2017 and has held it in 23 quarters since.
  • Natixis's DexCom position peaked at $99.7M in Q4 2021.
  • 960 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on Natixis's 13F filing for Q1 2026, filed 14 May 2026.